Normal view MARC view ISBD view

Hyperhomocysteinemia--a risk factor for abruptio placentae. [electronic resource]

By:

Owen, E P

Contributor(s):

Producer: 19971128Description: 359-62 p. digitalISSN:

0141-8955

Subject(s):

Online resources:

Available from publisher's website

In: Journal of inherited metabolic disease vol. 20

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

1 Pharmacokinetics of recombinant activated factor VII (rFVIIa).
by Erhardtsen, E
2 Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
by Hedner, U
3 Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model.
by Diness, V
4 Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
by Erhardtsen, E
5 The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits.
by Holm, P
6 The effect of recombinant aprotinin on t-PA-induced bleeding in rats.
by Erhardtsen, E
7 The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.
by Erhardtsen, E
8 Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.
by Girard, P
9 Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.
by Erhardtsen, E
10 Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.
by Konkle, B A
11 Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.
by Villar, A
12 Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study.
by Bernstein, D E
13 Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
by Jurlander, B